StockMarketWire.com - AstraZeneca said the U.S. Food and Drug Administration had decided against approving the company's application for its diabetes drug.

The drugmaker said it would work closely with the FDA to discuss the next steps after receiving a complete response letter from the US health regulator declining its application for using Farxiga.

Farxiga was recently approved in Europe (5mg) and Japan (5mg, potential up-titration to 10mg) under the name Forxiga, as an adjunct to insulin in adults with type-1 diabetes.




Story provided by StockMarketWire.com